Lv5
1115 积分 2021-02-07 加入
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
16小时前
已关闭
Dual-Action-Only PROTACs
8天前
已完结
The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation
9天前
已完结
In Vitro ADME Profiling of PROTACs: Successes, Challenges, and Lessons Learned from Analysis of Clinical PROTACs from a Diverse Physicochemical Space
12天前
已完结
Nonclinical teratogenicity safety assessment of CRBN-engaging targeted protein degraders: Points to consider
13天前
已完结
Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease
13天前
已完结
Human germline gain-of-function in STAT6: from severe allergic disease to lymphoma and beyond
13天前
已完结
Development of Substituted Phenyl Dihydrouracil as the Novel Achiral Cereblon Ligands for Targeted Protein Degradation
21天前
已完结
Turning Off STAT6 with a Targeted Degrader
22天前
已完结
Targeted protein degradation: from mechanisms to clinic
23天前
已完结
皖公网安备34019202002308
